Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 708 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorder, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-malignant Diseases Requiring Allogeneic HSCT
Interventions
IL-2
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Houston, Texas
Conditions
Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine, filgrastim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
23
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 18 more
Conditions
Hepatitis C
Interventions
Interleukin 2, Ribavirin, Pegylated Interferon Alpha, Inteleukin-2, Ribavirin + Pegylated interferon-alpha
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Allopurinol, Cyclophosphamide, Fludarabine phosphate, total-body irradiation, Allogeneic natural killer cells, Aldesleukin
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
Interventions
Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Leukemia, Pediatric Cancer
Interventions
Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 1Phase 2 Interventional

Dupilumab_Metastatic NSCLC

NCT05013450
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Dupilumab, PD-1/PD-L1 blockade, Anakinra
Drug
Lead sponsor
Thomas Marron
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Myelogenous Leukemia
Interventions
cytosine arabinoside (ara-C), daunomycin, interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions
locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2)
Biological · Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more
Conditions
Metastatic Colorectal Cancer
Interventions
Interleukin-2 (IL-2)
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
IL-2 Induced Hypotension
Interventions
M40403
Drug
Lead sponsor
MetaPhore Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Chicago, Illinois • Portland, Oregon • Salt Lake City, Utah
Conditions
Metastatic Renal Cell Carcinoma
Interventions
G250 peptide, IL-2
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Interventions
etakafusp alfa (AB248), pembrolizumab
Biological
Lead sponsor
Asher Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 15 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Biologic Therapy to Prevent Osteoarthritis After ACL Injury

NCT03968913
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Anakinra injection, sterile saline injection
Drug · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Neuroblastoma
Interventions
Interleukin-2
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Breast Cancer
Interventions
allogeneic large multivalent immunogen breast cancer vaccine, aldesleukin
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Acute Myocardial Infarction, Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 110 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes, in vitro-treated peripheral blood stem cell transplantation, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, filgrastim, aldesleukin
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoma
Interventions
aldesleukin, ganciclovir, zidovudine
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
IOV-2001, Low dose IL-2, High dose IL-2, IL-2
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Durham, North Carolina • Cincinnati, Ohio + 4 more
Conditions
HIV Infections
Interventions
Interleukin-2 SA, HAART
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more